Aegerion Pharma Loss Narrows; Stock Up 10%

(RTTNews) - Aegerion Pharmaceuticals Inc (AEGR) Tuesday reported second-quarter net loss of $9.6 million or $0.33 per share, compared with a loss of $19 million or $0.66 per share last year.

Excluding items, adjusted loss for the quarter was 0.06 per share, compared with a loss of $0.42 per share a year ago.

Revenue for the quarter was $36 million, compared with $6.5 million in the prior year.

Analysts polled by Thomson Reuters projected a loss of $0.41 per share on revenue of $35.4 million for the quarter.

Expenses were higher at $41 million, compared with $24 million last year.

Aegerion now expects full-year Juxtapid net product sales to be toward the lower end of the previously stated guidance range of between $180 million and $200 million. Juxtapid is indicated for the treatment of familial Hypercholesterolemia - a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein, in the blood and early cardiovascular disease.

Aegerion shares gained $2.88 or 9.41% at $33.50 in after-hours trade on the Nasdaq. The stock closed Tuesday at $30.62, up $0.55 or 1.83%.